Cambridge Healthtech Institute’s 4th Annual

iPS Cells for Disease Modeling and Drug Discovery

Pluripotent Stem Cells for Disease Research

June 19-20, 2019


With advances in reprogramming and differentiation technologies, as well as with the recent availability of gene editing approaches, we are finally able to create more complex and phenotypically accurate cellular models based on pluripotent cell technology. This opens new and exciting opportunities for pluripotent stem cell utilization in early discovery, preclinical and translational research. CNS diseases and disorders are currently the main therapeutic area of application with some impressive success stories resulted in clinical trials. Cambridge Healthtech Institute’s 4th Annual iPS Cells for Disease Modeling and Drug Discovery conference is designed to bring together experts and bench scientists working with pluripotent cells and end users of their services, researchers working on finding cures for specific diseases and disorders.

FEATURED SPEAKER: iPSC-Based Drug Discovery Platform for Targeting Innate Immune Cell Responses

Christoph Patsch, PhD, Team Lead Stem Cell Assays, Disease Relevant Cell Models and Assays, Chemical Biology, Therapeutic Modalities, Roche Pharma Research and Early Development

iPS CELLS FOR CNS DRUG DISCOVERY AND DEVELOPMENT

Preclinical Challenges for Gene Therapy Approaches In Neuroscience

Gabriele Proetzel, PhD, Director, Regenerative Medicine, Takeda Pharmaceuticals, Inc.

Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders

Thomas Durcan, PhD, Assistant Professor, Neurology and Neurosurgery, McGill University

IMPROVING iPSC-BASED TOOLS FOR MODELING

FEATURED PRESENTATION: Modeling Human Disease Using Pluripotent Stem Cells

Lorenz Studer, MD, Director, Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center

Exploring the Utility of iPSC-Derived 3D Cortical Spheroids in the Detection of CNS Toxicity

Colin Choi, PhD, Investigative Toxicologist, Takeda

Talk Title to be Announced

Yishan Sun, PhD, Investigator, Novartis Institutes for BioMedical Research (NIBR)

Rethinking the Translational – The Use of Highly Predictive hiPSC-Derived Models in Preclinical Drug Development
Stefan Braam, CEO,  Ncardia

Industrial-Scale Generation of Human iPSC-Derived Hepatocytes for Liver-Disease and Drug Development Studies

Liz Quinn, PhD, Associate Director, Stem Cell Marketing, Marketing, Takara Bio USA

iPSC-CARDIOMYOCYTES TO REVOLUTIONIZE DRUG DISCOVERY FOR HEART DISEASE

The Evolving Roles of Evolving Human Stem-Cell Derived Cardiomyocyte Preparations in Evolving Cardiac Safety Evaluations

Gary Gintant, PhD, Senior Research Fellow, AbbVie

HTS of iPSC-Cardiomyocytes

Arne Antoon N. Bruyneel, PhD, Postdoctoral Fellow, Mark Mercola Lab, Stanford University School of Medicine

Integrated Stress Response Regulates Cell Health of Cardiac Progenitors

Jeff Willy, PhD, Research Fellow, Discovery and Investigative Toxicology, Vertex

 


For more details on the conference, please contact:
Mana Chandhok
Conference Producer
Phone: 781-972-1350
Cambridge Healthtech Institute
Email: mchandhok@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com